Von Willebrand Disease Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Von Willebrand Disease Treatment Market Analysis
The Von Willebrand disease (VWD) treatment market is expected to register a CAGR of 6.5% during the forecast period.
The COVID-19 pandemic significantly impacted the studied market. As per a research article published in the ALM journal in September 2021, patients with COVID-19 significantly elevated levels of the von Willebrand factor (vWF) antigen, contributing to an increased risk of thrombosis that was seen in COVID-19-associated coagulopathy (CAC). As per the same source, the high levels of vWF antigen and activity have been clinically correlated with worse outcomes. Thus, it created opportunities for the availability of VWD treatment and impacted the market considerably. Therefore, COVID-19 impacted the studied market significantly and is expected to continue its strong growth over the forecast period.
Factors such as increased patient assistance programs and growing healthcare expenditure are expected to fuel the market's growth during the forecast period.
In July 2021, the PAN Foundation opened a new patient assistance program for people with VWD. The patients who qualify for this program receive USD 10,200 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with the treatment for the disease. Another initiative is the Octapharma Co-Pay Assistance Program. This program is available through Factor My Way and provides eligible patients with significant savings on some of the costs associated with their treatment. Such programs propel the demand for treating Von Willebrand's disease, contributing to the market's growth.
Furthermore, the incidence and prevalence of VWD disease are increasing globally and creating new opportunities for developing new drugs, therapies, and treatments available in the market. For instance, according to the Clinical guidelines for VWD published in January 2021 by the World Federation of Hemophilia (WFH), the annual prevalence of VWD ranges from 1 in 100 to 1 in 10,000 globally and requires medical attention for bleeding.
In addition, as per a research study published in the Journal of Blood Medicine in March 2023, approximately 0.6% - 1.3% of the general population was affected by VWD, and the prevalence of symptomatic VWD was approximately 10 per 100,000 during the study period of the research. This disease burden is attracting the focus of government bodies and market players toward the investments and development of innovative drugs, contributing to the studied market growth. Thus, the market is expected to grow over the forecast period due to the abovementioned factors.
However, the need for more awareness and the high cost of the treatment are the factors hindering the market growth.
Von Willebrand Disease Treatment Market Trends
Replacement Therapy Segment Expected to Register Significant Growth
The replacement therapy segment is anticipated to witness significant growth. Replacement therapy is referred to as the therapy involving the supply of a substance (such as a hormone or nutrient) lacking in or lost from the body. The replacement therapy segment is growing and is expected to grow over the analysis period.
Analysis of several studies and articles shows that treatment of VWD is primarily done with replacement therapy such as vWF and factor VIII plasma concentrates and recombinant vWF, which shows effective results among the patients. Hence, research is ongoing to evaluate the safety and efficacy of replacement therapies for VWD.
For instance, as per a research study published in the Blood Transfusion Journal in April 2022, a clinical trial program was conducted with a replacement therapy in pediatric patients treated with Wilfactin for up to 4.2 years, in 90.3% of episodes, good hemostatic efficacy was achieved and provided a safe and effective treatment in patients <6 years of age with severe VWD. Thus, such research with positive results creates demand for the availability of replacement therapies in the market and is expected to boost the segment's growth.
The increasing number of product approvals is one of the major factors fueling the segment's growth over the forecast period. Several market players are engaged in obtaining approvals for replacement therapies for the treatment of VWD. For instance, in June 2021, Takeda Pharmaceutical Company Limited reported that the USFDA accepted the supplemental Biologics License Application (sBLA) for VONVENDI, the first replacement therapy for prophylactic use in adults with VWD in the United States. This is meant for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults (aged 18 years and older) with VWD. Thus, the segment is expected to grow significantly over the forecast period due to the factors mentioned above.
North America is Expected to Have a Major Market Share
North America holds a significant market share and is expected to continue the trend during the analysis period. The factors attributing to the high market share of North America are the consistent focus on cost-effective and innovative drugs and the increasing prevalence of the disease across the countries in the region.
The United States, among other countries, has shown a growing trend in the studied market. The major factors contributing to the market growth in the United States are the rising incidence of Von Willebrand disease, the growing number of strategic initiatives, and the growing number of patient assistance programs. For instance, as per the update by the CDC in April 2021, VWD is the most common bleeding disorder in the United States, and 3.2 million people in the country had the disease in recent years. In addition, as per the 2023 data update by the National Hemophilia Foundation, 1 in 100 people in the United States are found to have VWD every year. Therefore, this burden of the disease is creating a significant demand for the availability of innovative treatments for this disease in the country, contributing to the overall market growth in the region.
There are several initiatives to raise awareness, and product approvals of VWD are fueling market growth. For instance, in June 2021, the USFDA granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A. Efanesoctocog alfa is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeds with once-weekly prophylactic dosing for people with hemophilia A. It builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN polypeptides to extend its time in circulation. Thus, the region is expected to grow significantly during the forecast period due to the factors mentioned above.
Von Willebrand Disease Treatment Industry Overview
The Von Willebrand disease treatment market, is competitive, with the presence of many global players. The most prominent players in the market are Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical, and Takeda.
Von Willebrand Disease Treatment Market Leaders
-
CSL Behring
-
Grifols, S.A.
-
Takeda Pharmaceutical Company Ltd
-
Octapharma AG
-
Bio Products Laboratory Ltd.
*Disclaimer: Major Players sorted in no particular order
Von Willebrand Disease Treatment Market News
- February 2023: the USFDA approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is a novel von Willebrand Factor (VWF) independent recombinant factor VIII therapy that is designed to extend protection from bleeds with once-weekly prophylactic dosing for adults and children with hemophilia A.
- April 2022: Octapharma became a Gold Sponsor of the upcoming World Federation of Haemophilia (WFH) 2022 World Congress, taking place from May 8 to 11, 2022. Octapharma will highlight key unmet needs of people living with von Willebrand disease (VWD) during a live symposium.
- January 2022: Takeda received USDFDA approval for VONVENDI [von Willebrand Factor (Recombinant)] for routine prophylaxis treatment in patients with severe type 3 von Willebrand disease receiving on-demand therapy.
Von Willebrand Disease Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increase in Patient Assistance Programs
- 4.2.2 Growing Healthcare Expenditure
-
4.3 Market Restraints
- 4.3.1 Lack of Awareness
- 4.3.2 High Cost of Treatment
-
4.4 Porter Five Forces
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Disease Type
- 5.1.1 Type 1
- 5.1.2 Type 2
- 5.1.3 Type 3
- 5.1.4 Acquired VWD
-
5.2 By Treatment Type
- 5.2.1 Desmopressin
- 5.2.2 Replacement Therapies
- 5.2.3 Clot-stabilizing Medications
- 5.2.4 Other Treatment Types
-
5.3 By Route of Administration
- 5.3.1 Oral
- 5.3.2 Injection
- 5.3.3 Other Routes of Administration
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 CSL Behring
- 6.1.2 Ferring Pharmaceuticals
- 6.1.3 Grifols SA
- 6.1.4 Octapharma AG
- 6.1.5 Pfizer Inc.
- 6.1.6 Sanofi SA
- 6.1.7 Takeda Pharmaceutical Company Ltd
- 6.1.8 Bio Products Laboratory Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityVon Willebrand Disease Treatment Industry Segmentation
As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by a missing or defective Von Willebrand factor (VWF), a clotting protein. The Von Willebrand Disease Treatment Market is Segmented by Disease Type (Type 1, Type 2, Type 3, and Acquired VWD), Treatment Type (Desmopressin, Replacement Therapies, Clot-Stabilizing, and Other Treatment Types), Route of Administration (Oral, Injection, and Other Routes of Administration), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for the above segments.
| By Disease Type | Type 1 | |
| Type 2 | ||
| Type 3 | ||
| Acquired VWD | ||
| By Treatment Type | Desmopressin | |
| Replacement Therapies | ||
| Clot-stabilizing Medications | ||
| Other Treatment Types | ||
| By Route of Administration | Oral | |
| Injection | ||
| Other Routes of Administration | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Von Willebrand Disease Treatment Market Research FAQs
What is the current Global Von Willebrand Disease Treatment Market size?
The Global Von Willebrand Disease Treatment Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Global Von Willebrand Disease Treatment Market?
CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Ltd, Octapharma AG and Bio Products Laboratory Ltd. are the major companies operating in the Global Von Willebrand Disease Treatment Market.
Which is the fastest growing region in Global Von Willebrand Disease Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Von Willebrand Disease Treatment Market?
In 2024, the North America accounts for the largest market share in Global Von Willebrand Disease Treatment Market.
What years does this Global Von Willebrand Disease Treatment Market cover?
The report covers the Global Von Willebrand Disease Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Von Willebrand Disease Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Von Willebrand Disease Treatment Industry Report
Statistics for the 2024 Von Willebrand Disease Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Von Willebrand Disease Treatment analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
